Research programme: PEGylated recombinant interleukin-11 protein - ViroMed

Drug Profile

Research programme: PEGylated recombinant interleukin-11 protein - ViroMed

Alternative Names: NL 002 1; PEG-VM 501

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ViroMed Co Ltd
  • Developer ViroMed
  • Class Interleukins; Recombinant proteins
  • Mechanism of Action Haematopoiesis stimulants; Interleukin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Thrombocytopenia

Highest Development Phases

  • No development reported Thrombocytopenia

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Thrombocytopenia(Chemotherapy-induced) in South Korea (SC, Injection)
  • 27 May 2013 PEG-VM501 is available for licensing worldwide (excluding China) once it enters clinical development.
  • 01 May 2013 Preclinical development is ongoing in South Korea
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top